In spite of a great improvement in medical health services and an increase in lifespan, we
have witnessed a skyrocket increase in the incidence of central nervous system (CNS) …

This review summarizes 30 years of experience in the development and clinical use of
magnetic resonance (MR) contrast agents. Despite their undisputable usefulness for …

Objectives The aim of this report was to characterize the key physicochemical,
pharmacokinetic (PK), and magnetic resonance imaging (MRI) properties of gadoquatrane …

Background Gadolinium-based contrast agents were not approved in the United States for
detecting coronary artery disease (CAD) prior to the current studies. Objectives The purpose …

Gadolinium‐based contrast agents (GBCAs) are widely and routinely used to enhance the
diagnostic performance of magnetic resonance imaging and magnetic resonance …

Metastasis is the leading cause of cancer-related death. However, it remains a poorly
understood aspect of cancer biology, and most preclinical cancer studies do not examine …

Background Understanding molecular transport in the brain is critical to care and prevention
of neurological disease and injury. A key question is whether transport occurs primarily by …

Abstract Rationale: Image-guided, triggerable, drug delivery systems allow for precisely
placed and highly localised anti-cancer treatment. They contain labels for spatial mapping …

The PEGylated ultrasmall iron oxide nanoparticles (PUSIONPs) exhibit longer blood
residence time and better biodegradability than conventional gadolinium‐based contrast …

Purpose Low molecular weight iron (III) complex‐based contrast agents (IBCA) including
iron (III) trans‐cyclohexane diamine tetraacetic acid [Fe (tCDTA)]− could serve as …